Feb 01, 2021: “Chiesi, an international research-focused healthcare group (Chiesi Group), announces that the European Commission has granted the marketing authorisation for Trimbow (beclometasone/formoterol/glycopyrronium), an extrafine formulation triple fixed combination therapy in a single inhaler, as a maintenance treatment for adult asthma patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist (LABA) and medium dose of inhaled corticosteroid (ICS), who experienced one or more asthma exacerbations in the previous year.
This follows the 2017 approval of this therapeutic option for the treatment of adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS/LABA, or a combination of a LABA/LAMA (long-acting muscarinic antagonist).
Chiesi’s triple therapy is a combination of an ICS/LABA/LAMA that contains beclometasone dipropionate (ICS), formoterol fumarate (LABA) and glycopyrronium (LAMA).
For asthma, this is the first triple, extrafine formulation, combination inhaler with the ability to reach the whole bronchial tree, including both the large and the small airways.
The inhaler also contains a dose counter that allows patients to track and manage their treatment.
“This is the first step towards taking our triple therapy for moderate to severe COPD patients and providing the same treatment option for appropriate asthma patients,” said Alessandro Chiesi, Chiesi Group Chief Commercial Officer.
“Chiesi is committed to developing and delivering alternatives to aid patients in the management of their respiratory conditions and treatment.
The European Commission’ approval brings us one step closer to providing uncontrolled adult asthma patients with a new treatment option for their care, reducing exacerbations and potentially simplifying the use for patients, thanks to a single inhaler triple therapy.”
Asthma is a chronic inflammatory disease affecting over 339 million people worldwide.
According to GINA, people with uncontrolled asthma have poor symptom control and/or frequent exacerbations requiring oral corticosteroids or experience serious exacerbations requiring hospitalisation.
In patients with uncontrolled asthma, Chiesi triple therapy has been shown to reduce exacerbations and improve lung function in comparison to ICS/LABA.
The CHMP recommendation and the European Commission decision are based on the efficacy and safety data of four clinical studies involving close to 3000 patients.”
https://www.chiesi.com/en/chiesi-group-receives-the-european-marketing-authorisation-for-trimbowr–28beclometasone-dipropionate-2C-formoterol-fumarate-2C-glycopyrronium-29-an-extrafine-formulation-fixed-triple-combination-therapy-for-the-treatment-of-asthma/
